

Drugs in Clinical Trials for Schizophrenia

Created and updated by Hugo Geerts, In Silico Biosciences

Last updated 15 January, 2007

General Disclaimer

Important note: This database is designed to be used by researchers. Patients and caregivers are directed to consult Clinicaltrials.gov for more information on how to enroll in specific trials. (See also Schizophrenia.com page on [Medications in Development](#)) Neither Schizophrenia Research Forum nor the author(s) of these data will respond to specific questions from the public about the information in this table. Schizophrenia Research Forum does not provide medical advice or promote any product or service. The contents are for informational purposes only and are not intended to substitute for professional medical advice, diagnosis or treatment. Always seek advice from a qualified physician or health care professional about any medical concern, and do not disregard professional medical advice because of anything you may read on this web site.

The overarching goal of this database is to serve as an unbiased, centralized, publicly available and regularly updated collection of ongoing clinical studies in schizophrenia. The primary goal is also to provide information on trials where reducing clinical symptomatology (i.e., positive, negative, and cognitive deficits) in schizophrenia is a primary goal, rather than trials where specific comedications are tested to address drug-specific side-effects. To ensure a high degree of objectivity regarding the posted information, only publicly available information, such as found on the [U.S. Government Clinical Trials](#) website or the [Stanley Medical Research Foundation](#) website, in addition to specific company websites, is used for inclusion into the database.

While we have made every possible effort to correctly represent the data of all studies fulfilling the above criteria we cannot exclude the possibility that some studies are cited incorrectly or were erroneously excluded. Therefore, we are not able to make any warranty, either expressed or implied, with respect to the functioning and accuracy of this database. No responsibility is assumed by the authors and curators.

If you detect an error in the data or want to submit general concerns, comments and suggestions about the database, please [contact us](#). We encourage clinicians responsible for novel investigator initiated clinical trials to [submit your data](#).

Line #	Phase	Drug	Sponsors	Mode of Action	Other Names	Clin Trial ID	Putative Role in SZ/Notes	Useful Links
1	1	AZD-9272	AstraZeneca-NPS Pharma	mGluR1 antagonist			Addresses NMDA dysfunction	Brody et al., 2003
2	1	BL-1020	Bio-LineRx	Dopamine antagonist with GABA modulation			Dopamine antagonist + addresses possible GABA dysfunction	
3	1	Chelerythrine	Marinus Pharma	PKC inhibitor			Improves PFC working memory, possibly through adrenergic pathway	Hahn and Friedman, 1999
4	1	CRD-101	Curidium	Unknown			CNS modulator	Company website
5	1	GSK189254	GSK	H3 antagonist			Histamine dysregulation in schizophrenia; possibly addresses cognitive deficit in schizophrenia	Ito, 2004

Line #	Phase	Drug	Sponsors	Mode of Action	Other Names	Clin Trial ID	Putative Role in SZ/Notes	Useful Links
6	1	GSK644784	GSK	COX2 inhibitor			Tests hypothesis of immune contribution to SZ	Company website
7	1	Idazoxan	Potomac Pharma	α2 AR			Addresses noradrenergic deficiency in negative symptoms	Wadenberg et al., 2006
8	1	JNJ17305600	Allelix/J&J	GlyT1 inhibitor			Addresses NMDA dysfunction	Harsing et al., 2006
9	1	LAX101	Amarin	Phospholipase inhibitor	Miraxion		Neuroprotective, anti-inflammatory, also in development for Huntington, Parkinson's, bipolar, and depression	Peet, 2003
10	1	LX6171	Lexicon	LG 617 R antagonist			Novel target associated with presynaptic membranes and vesicles; Cognitive enhancer add-on	Company website
11	1	MEM1003	Memory	L-type Ca channel blocker	BAY-Z-4406		Brain penetrant nimodipine analog Add-on for cognitive disorder	Rose, 2006
12	1	MEM-3454	Memory Pharma/Roche	α7 nAChR agonist			Cognitive enhancer add-on also in development for AD	Mazurov, 2006
13	1	Neboglamine	Rottapharm	Glycine site pos modulator	XY-2401		Addresses NMDA dysfunction for cognitive enhancement	Company website
14	1	ORM10921	Orion	α2C antagonist			Addresses noradrenergic deficiency in negative symptoms	Company website
15	1	PF00184562	Pfizer	Unknown				NCT00150215
16	1	PNU177864	Pfizer	D3 antagonist			Addresses subcortical DA dysfunction	Kafka et al., Society for Neuroscience Abstracts, 2000, 26 :1-2
17	1	PRX 07034	Epix	5-HT6 antagonist			Improves memory consolidation; cognitive add-on	Company website
18	1	PW4123	PennWest	CNS modulator			Also in development for epilepsy	Company website
19	1	RG1068	Indiana University School of Medicine/Repligen	Secretin		NCT00235274	Improves pair-pulse inhibition	Sheitman et al., 2004
20	1	RGH188	Gedeon Richter/Forest	D2/D3 antagonist		NCT00404573	Dopamine antagonist	Kiss et al., Society for Neuroscience Abstracts, 2006.
21	1	SGS518	Saegis Pharma/Lilly	5-HT6 antagonist			Improves memory consolidation; Cognitive enhancer add-on	Company website
22	1	SLV 314	Solvay/Wyeth	D2 antagonist/SSRI			Combines serotonin modulation for negative symptoms	Company website

Line #	Phase	Drug	Sponsors	Mode of Action	Other Names	Clin Trial ID	Putative Role in SZ/Notes	Useful Links
23	1	SLV 319	Solvay/Wyeth	D2 antagonist 5-HT1A agonist CB1 antagonist			Regulates dopamine and glutamate neurotransmission	Company website
24	1	SSR504734	Sanofi	GlyT1 inhibitor			Addresses NMDA dysfunction; Cognitive enhancer add-on	Depoortere et al., 2005
25	1	Unnamed	BioValve	D1 agonist				Stanley Medical Research Foundation
26	1	YKP1358	SK Bio-Pharmaceuticals	D2/ D3/ 5-HT-2A antagonist, no act at adrenergic receptors			Serotonin-dopamine stabilizer	Company website
27	1	ACR16	Carlsson Research	D2 partial agonist			Serotonin-dopamine stabilizer (Positive Ph II data in Huntington's)	Natesan et al., 2006
28	1	ACR325	Carlsson Research	D2 partial agonist			Serotonin-dopamine stabilizer	Company website
29	1	AV1625	Sanofi	CB1 antagonist			Cannabinoid modulation; increases cholinergic and glutamatergic neurotransmission	Diu-Hercend et al., Society for Neuroscience Abstracts2005.
30	1	GSK773812	GSK	D2 5-HT2 antagonist		NCT00259870	Serotonin-dopamine antagonist (SDA)	Company website
31	1	Stepholidine	University of Toronto/Stanley Medical Research Foundation	D2 antagonist D1 agonist			Derived from Chinese herbs	Jin et al., 2002 Stanley Medical Research Foundation
32	2	ACP104	Acadia Pharma	N-desmethylozapine			Major metabolite of clozapine ; Attempt to capitalize on good clozapine pharmacology	Davies et al., 2005
33	2	DAR0100-dihyrexidine	Purdue Pharma-DAR Pharma	Partial D1 agonist for negative symptoms	N-(n-propyl)-dihyrexidine		Improves cognition	Doll, 1999
34	2	G773812	GSK	DA/5-HT2 antagonist		NCT00259870	Serotonin-dopamine antagonist (SDA)	Company website
35	2	D-serine	A number of studies in progress	NMDA enhancer		NCT00138775 NCT00322023 NCT00237848 NCT00215917 NCT00237809	Direct activator of glycine site on NMDA receptor; Cognitive enhancer add-on; Patients with persistent negative and cognitive deficits	Tamminga, 2006 See also Stanley Medical Research Foundation

Line #	Phase	Drug	Sponsors	Mode of Action	Other Names	Clin Trial ID	Putative Role in SZ/Notes	Useful Links
36	2	ABT089	Abbott	nAChR agonist			Nicotinic ACh receptor modulator; Cognitive enhancer add-on; now in development for ADHD	Reuter et al., 2004
37	2	CX516	North Suffolk Mental Health Association/ Cortex	Ampakine		NCT00235352	Positive modulator of AMPA subtype of glutamate receptor; Cognitive enhancer add-on	Danysz, 1999
38	2	Org24448	TURNS/Organon	Ampakine	CX691	NCT00425815	Positive modulator of AMPA subtype of glutamate receptor; Cognitive enhancer add-on supported by MATRICS http://www.matrics.ucla.edu/	TURNS
39	2	SGS518	Lilly/Saegis	5-HT6 antagonist			Improves memory consolidation; cognitive enhancer add-on	Company website
40	2	SB 742457	GSK	5-HT6 antagonist			Improves memory consolidation	Company website
41	2	Ocaperidone	Neuro3D	D2 5-HT2 antagonist			Serotonin-dopamine antagonist (SDA)	Company website
42	2	Rimonabant	Sanofi	CB1 antagonist			Cannabinoid modulation (Already approved for weight loss; tested in smoking cessation)	Gelfand and Cannon, 2006
43	2	Sabcomeline	Minster Research	M1 ACh agonist	SB-202026		Treatment of cognitive decline (Previously tested in AD)	Louden et al., 1997
44	2	Talnetant	GSK	Neurokinin3 antagonist		NCT00103727 NCT00300963 NCT00049946	Improves positive symptoms	Evangelista, 2005
45	2	Lurasidone	Dainippon/ Sumitomo/Merck	D2 antagonist 5-HT2A antagonist	SM13496		Serotonin-dopamine antagonist (SDA)	Company website
46	2	Ispronicline	AstraZeneca/ Targacept	nAChR agonist	TC1374		Nicotinic ACh receptor modulator (Cognitive enhancer add-on)	Geerts, 2006
47	2	Vabicaserin	Wyeth	5-HT2C agonist, 5-HT2B antagonist	SCA136, WAY161503	NCT00265551	Mood stabilizer	Mosher et al., 2006 NCT00420706

Line #	Phase	Drug	Sponsors	Mode of Action	Other Names	Clin Trial ID	Putative Role in SZ/Notes	Useful Links
48	2	EPO	Max Planck Inst.	Neuroprotectant			Higher number of receptors in hippocampus/ cortex of SZ patients (Cognitive enhancer add-on)	Ehrenreich et al., 2004 SRF news story Ehrenreich et al., 2006
49	2	Sarcosine	Herzog Hospital, Israel	NMDA enhancer		NCT00276263	Addresses NMDA dysfunction	Lindsley et al., 2006
50	2	GTS21	University of Florida	nAChR agonist	DMBX-A		Partial α7 nicotinic ACh receptor modulator (Proof-of-concept study successful)	Olincy et al., 2006
51	2	Preclamol	University of Maryland	D2 agonist	(-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine ((-)-3PPP)		Partial D1 agonist (Cognitive enhancement)	Tamminga, 2002
52	2	Tetrabenazine	University of Toronto/ Stanley Medical Research Foundation	Monoamine depleting agents		NCT00362804	Augmentation to neuroleptic, depletes presynaptic DA	
53	2	Taurine	University of Melbourne/Stanley Medical Research Foundation	Essential amino acid		NCT00420823	Add-on; restore putative astrocytic dysfunction	
54	2	Arthemeter	Wuhan University China	Antibiotic			Repurposed anti- malaria and toxoplasmosis add-on	Caramello et al., 2005
55	2	Curcumin	University of Western Ontario	Anti-inflammation			Test immunological hypothesis in SZ Antioxidant, inhibits MAPK and NFkB	Stanley Medical Research Foundation
56	2	BF2.649	University of Texas Southwestern/Stanley Medical Research Foundation	H3 antagonist			Histamine dysregulation in schizophrenia; Add-on for cognitive disorders	Ligneaux, 2006 Stanley Medical Research Foundation
57	2	Epigallocatechin gallate	Portland VA/Stanley Medical Research Foundation	Inhibition of NO			Neuroprotectant; NFkB inhibitor (Green tea polyphenol; add-on)	Nam, 2006 Stanley Medical Research Foundation

Line #	Phase	Drug	Sponsors	Mode of Action	Other Names	Clin Trial ID	Putative Role in SZ/Notes	Useful Links
58	2	L-carnosine	Pittsburgh Western Psychiatric Institute and Clinic/Stanley Medical Research Institute	Antioxidant and anti-glycolysilation		NCT00177177	Cognitive enhancer	Ignacio et al., 2005
59	2	Raloxifene, estradiol 2mg plus dyhydroprogesterone	Victoria, Australia; Alfred Hospital/Monash University	Adjunctive estrogen			Add-on to clozapine in women	Stanley Medical Research Institute
60	2	B12, folic acid, and pyridoxine	University of Melbourne, Victoria, Australia	Antioxidants			Neuroprotective add-on	Stanley Medical Research Institute
61	2	Valproate	Beijing Anding Hospital, Capital University of Medical Sciences	Ion channel modulator			Add-on	Stanley Medical Research Institute
62								
63	2	Celecoxib	Beijing Hui-Long-Guan Hospital	COX inhibitor			Add-on Test immunological hypothesis in SZ	Stanley Medical Research Institute
64	2	Transdermal nicotine	Harvard Medical Center	Stimulates nAChR			Cognitive enhancer add-on ; stimulator	Stanley Medical Research Institute
65	2	Memantine + donepezil	University of California, Irvine	NMDA antagonist + AChE inhibitor			Increases signal-to-noise of cerebral information processing	Geerts and Grossberg, 2006 Stanley Medical Research Institute
66	2	Raloxifene	Sant Joan de Deu-Serveis de Salut Mental, Barcelona, Spain				Specific estrogen modulator; Add-on in women; for negative symptoms	Stanley Medical Research Institute
67	2	Memantine	Charite Hospital, Berlin, Germany	NMDA antagonist		NCT00148590	Add-on for prevention of negative symptoms	
68	2	Memantine	Charite Hospital, Berlin, Germany	NMDA antagonist		NCT00148616	Add-on for treatment of negative symptoms and cognitive impairment	

Line #	Phase	Drug	Sponsors	Mode of Action	Other Names	Clin Trial ID	Putative Role in SZ/Notes	Useful Links
69	2	Lamotrigine/minocycline	University of Manchester/Stanley Medical Research Foundation	Na-channel blocker; anticonvulsant			Add-on Neuroprotective	Miyaoka, 2006 Stanley Medical Research Institute
70	2	Pioglitazone	NYU School of Medicine and Manhattan Psychiatric Center/Stanley Medical Research Foundation	PPARG agonist		NCT00231894	Add-on ; Addresses metabolic syndrome induced by clozapine & olanzapine	Seeburg, 2001
71	2	Simvastatin	Columbia University, New York	Cholesterol-lowering			Add-on	Stanley Medical Research Institute
72	2	Pramipexol	St. Vincent's Hospital Westchester, Hanover, NJ/Stanley Medical Research Foundation	D3 agonist			Improves cognitive deficit; add-on	Kasper et al., 1997 Stanley Medical Research Institute
73	2	Bexarotene	Ben-Gurion University of the Negev, Beersheba, Israel/Stanley Medical Research Foundation	Retinoid X receptor antagonist		NCT00141947	Dysregulation of retinoic metabolism	Farol and Hymes, 2004
74	2	Dipyridamole	University of Maryland	Adenosine agonist		NCT00349973	Adenosine-glutamate enhancement	Brunstein et al., 2001
75	2	Tolcapone	NIMH	COMT inhibitor		NCT00044083	Enhances DA neurotransmission in prefrontal cortex; add-on for cognitive disorder	Tunbridge et al., 2004
76	2	Modafinil	A number of studies in progress	DA outflow enhancer		NCT00057707 NCT00423943 NCT00314639 NCT00373672	Enhances DA neurotransmission in prefrontal cortex, COMT genotype sensitive	Rosenthal and Bryant, 2004

Line #	Phase	Drug	Sponsors	Mode of Action	Other Names	Clin Trial ID	Putative Role in SZ/Notes	Useful Links
77	2	Pregnenolone	Sha'ar Menashe Mental Health Center, Beershava, Israel	Neurosteroid, affecting GABA		NCT00174889	Enhances GABA neurotransmission	Marx et al., 2006
78	2	Escitalopram	Several studies in progress	5-HT transporter inhibitor		NCT00148447 NCT00231335	Add-on : Treatment of negative symptoms	Van Knorring et al., 2006
79	2	Folate, VitB12, piridoxine	Nathan Klein Institute/Stanley Medical Research Foundation	Vitamin		NCT00403247	Lowers high homocysteine levels; add-on therapy	Muntjewerff et al., 2006 Stanley Medical Research Institute
80	2	Estradiol	Several studies in progress	Hormonal substitution		NCT00206570 NCT00357006	Specific estrogen modulator, improves negative symptoms; add-on in women only	Rasgon et al., 2002
81	2	Riluzole	Yale University/Stanley Medical Research Foundation	NMDA antagonist		NCT00375050	Neuroprotective; Add-on for cognitive disorders; approved for ALS	Seppi et al., 2001 Stanley Medical Research Institute
82	2	Creatine	Beersheva Mental Health Center/NARSAD	Energy enhancer		NCT00140192	Improves working memory; Add-on for cognitive disorders	Rae et al., 2003
83	2	Entacapone	Several studies in progress	COMT inhibitor		NCT00192855 NCT00044083	Enhances DA neurotransmission in prefrontal cortex; Add-on for cognitive disorders; COMT sensiitve	Tunbridge et al., 2004
84	2	Tiagabine	Beth Israel Deaconess Medical Center	GABA enhancer		NCT00179465	Addresses GABA deficiency; add-on	Woo and Crowell, 2005
85	2	W3 fatty acids	University of Pittsburgh/ American Heart Association/ VA Pittsburgh Healthcare System	Cardiac protection		NCT00167310	Add-on	

Line #	Phase	Drug	Sponsors	Mode of Action	Other Names	Clin Trial ID	Putative Role in SZ/Notes	Useful Links
86	2	L-830982	University of Pittsburgh/Merck	GABA α2/3 agonist		NCT00129441	Addresses GABA dysfunction; Add-on for cognitive disorders and general anxiety	
87	2	Glycine	Several trials in progress	Direct agonist of the glycine site on NMDA-R		NCT00291226 NCT00338598 NCT00322023 NCT00215917	Addresses NMDA dysfunction	Lindsley et al., 2006
88	2	Cannabidiol	University of Cologne, Germany/Stanley Medical Research Foundation	Endocannabinoid		NCT00309413	Tests cannabinoid approach	Zuardi et al., 2006 Stanley Medical Research Institute
89	2	Low dose lithium	Melbourne Health, Australia	GSK3 inhibitor		NCT00202306	Test hypothesis that cytoskeletal tau-abnormalities might be involved in SZ; prevention	Deutsch et al., 2006
90	2	Valacyclovir	University of British Columbia	Antiviral		NCT00175513	Test hypothesis that SZ might be caused by viral infections	
91	2	Org 34517	Weil medical College of Cornell University	Selective glucocorticoid receptor antagonist		NCT00226278	Restores limbic-hypothalamic-pituitary-adrenal dysfunction; add-on	Bachmann et al., 2003
92	3	L-Theanine	Sha'ar Menashe Mental Health Center		gamma-glutamylethylamide	NCT00372151	Enhances glutamate neurotransmission; Add-on for cognitive disorders	Yamada et al., 2005
93	3	Lamotrigine	GSK	Na-channel blocker; anticonvulsant		NCT00071747	Addresses GABA pathology; Add-on therapy	Premkumar and Pick, 2006
94	3	Bifeprunox	Solvay/Wyeth	5-HT2A/D2 partial agonist		NCT00366327 NCT00366704 NCT00347425 NCT00366171	Serotonin-dopamine antagonist (SDA)	Cosi et al., 2006

Line #	Phase	Drug	Sponsors	Mode of Action	Other Names	Clin Trial ID	Putative Role in SZ/Notes	Useful Links
95	3	Asenapine	Organon/Pfizer	5-HT2/D2 antagonist	Org5222	NCT00156104 NCT00150176 NCT00212836 NCT00145496 NCT00156065 NCT00156091 NCT00174265 NCT00265343 NCT00281320	Serotonin-dopamine antagonist (SDA)	Audinot et al., 2001
96	3	Paliperidone	Janssen/Johnson & Johnson	5-HT2/D2 antagonist	9-OH Risperidone, Invega	NCT00334126 NCT00396565 NCT00350467	Serotonin-dopamine antagonist (SDA)	Nesvag et al., 2006
97	3	Paliperidone palmitate	Johnson & Johnson	5-HT2/D2 antagonist	9-OH Risperidone, Invega	NCT00210548	Serotonin-dopamine antagonist (SDA); Long-acting depot formulation	Nesvag et al., 2006
98	3	Blonanserine	Dainippon	5-HT2/D2 antagonist	AD5423		Serotonin-dopamine antagonist (SDA)	[No authors listed], 2002
99	3	Mifepristone	Corlux	Glucocorticoid-R antagonist	RU-486		Restores limbic-hypothalamic-pituitary-adrenal dysfunction; Psychotic depression	Gallagher et al., 2005
100	3	Iloperidone depot	Vanda	Dopamine-R/5-HT2 antagonist		NCT00254202	Serotonin-dopamine antagonist (SDA)	Hesselink, 2002
101	3	Atomoxetine	Several trials in progress	NE/5-HT transporter inhibitor		NCT00216281 NCT00420498 NCT00161031	Add-on for cognitive therapy	
102	4	Divalproex sodium	Vanderbilt	Na channel modulator		NCT00306475	Add-on for cognitive therapy	Basan et al., 2004
103	4	Pimozide	Several trials in progress	Antipsychotic		NCT00158223 NCT00374244	Serotonin-dopamine antagonist (SDA); antipsychotic, possible effects on negative symptoms	Sultana and McMonagle, 2000
104	4	Galantamine	Several trials in progress	AChE inhibitor, nAChR modulator		NCT00176423 NCT00232349	Add-on for cognitive deficiency	Friedman, 2004

Line #	Phase	Drug	Sponsors	Mode of Action	Other Names	Clin Trial ID	Putative Role in SZ/Notes	Useful Links
105	4	Pravastatin	University of Pittsburgh	Cholesterol-lowering		NCT00177580	Improves residual & cognitive functions; add-on	
106	4	Duloxetine	Mental Health, Mannheim, Germany	5-HT/NE transporter inhibitor		NCT00224302	Add-on for negative symptoms	Zink et al., 2006
107	4	Riluzole	Univ of Munich	Glutamate modulator		Stanley 03T-350	Added to risperidone	Stanley Medical Research Institute